Substance Abuse Treatment Market Size, Share, Growth, Trends | Report 2023-2032
The global substance abuse treatment market was estimated at USD 11.09 billion in 2022 and it is expected to surpass around USD 25.15 billion by 2032, poised to grow at a CAGR of 8.53% from 2023 to 2032.
Key Pointers
Report Scope of the Substance Abuse Treatment Market
| Report Coverage | Details |
| Market Size in 2022 | USD 11.09 billion |
| Revenue Forecast by 2032 | USD 25.15 billion |
| Growth rate from 2023 to 2032 | CAGR of 8.53% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Companies Covered | Abbott; Teva Pharmaceutical Industries Ltd., GSK plc.; Eli Lilly and Company; Cipla Inc.; Novartis AG; AstraZeneca, Alkermes, and Mallinckrodt. |
The growth of substance abuse treatment market is attributed to the increasing demand for therapeutic options to meet the rising prevalence rate of addicted population. With the increasing addiction population, there is an increasing interest of market players in development of novel treatments to meet the surge in demand for substance abuse therapeutics. Moreover, increasing drug awareness campaigns and rehabilitation programs are expected to further propel the demand for effective therapeutic alternatives.
Increasing global initiatives to create awareness amongst the addicted population is one of the major factors driving market growth. For instance, the WHO celebrates World No Tobacco Day on May 31 each year globally. In addition, in June 2021, DC Health launched public education campaign MyRecoveryDC, for helping addicted individuals to help them provide access to treatment and recovery services addicted to alcohol, drugs, and alcohol. Moreover, in October 2022, Qnovia raised USD 17 million for fighting against nicotine addiction.
Substance abuse kills around 11.8 million people worldwide. The major proportion of the population is addicted to alcohol and tobacco which makes it a major public health problem. There are various steps have been taken for encouraging several awareness-raising activities with the help of contributions from individuals, private sector organizations, and non-profit organizations. These global steps are helping individuals to opt for de-addiction therapies thereby driving market growth.
North America dominated the overall market in 2022 which can be attributed to the growing population exposed to addiction, legalization of marijuana in various states, well-structured reimbursement policies, and the developed healthcare sector with effective therapeutics for drug addiction, which is supporting the growth of the market in this region. It is estimated that around 21 million people in the region have at least 1 addiction, which usually starts with alcohol which is one of the most widely abused substances eventually leading to the abuse of opioids, marijuana, nicotine, heroin, and cocaine. These substances generally affect the brain’s normal function and lead to harmful consequences on a person’s health. However, to tackle and provide treatment for such additions, the region has a presence of organizations such as the American Society of Addiction Medicine, which is home to addiction medicine specialists and physicians.
Substance Abuse Treatment Market Segmentations:
| By Treatment | By Distribution Channel |
|
Alcohol Addiction Treatment Tobacco/Nicotine Addiction Treatment Opioid Addiction Treatment Other |
Hospital Pharmacies Retail Pharmacies Other Distribution Channels |
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Substance Abuse Treatment Market
5.1. COVID-19 Landscape: Substance Abuse Treatment Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Substance Abuse Treatment Market, By Treatment
8.1. Substance Abuse Treatment Market, by Treatment, 2023-2032
8.1.1. Alcohol Addiction Treatment
8.1.1.1. Market Revenue and Forecast (2020-2032)
8.1.2. Tobacco/Nicotine Addiction Treatment
8.1.2.1. Market Revenue and Forecast (2020-2032)
8.1.3. Opioid Addiction Treatment
8.1.3.1. Market Revenue and Forecast (2020-2032)
8.1.4. Other
8.1.4.1. Market Revenue and Forecast (2020-2032)
Chapter 9. Global Substance Abuse Treatment Market, By Hospital Pharmacies
9.1. Substance Abuse Treatment Market, by Distribution Channel, 2023-2032
9.1.1. Hospital Pharmacies
9.1.1.1. Market Revenue and Forecast (2020-2032)
9.1.2. Retail Pharmacies
9.1.2.1. Market Revenue and Forecast (2020-2032)
9.1.3. Other Distribution Channels
9.1.3.1. Market Revenue and Forecast (2020-2032)
Chapter 10. Global Substance Abuse Treatment Market, Regional Estimates and Trend Forecast
10.1. North America
10.1.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.1.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.1.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.1.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.2.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.2.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.2.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.2.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.2.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.3.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.3.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.3.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.3.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.4.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.4.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.4.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.4.6.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.5.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.5.3.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Treatment (2020-2032)
10.5.4.2. Market Revenue and Forecast, by Distribution Channel (2020-2032)
Chapter 11. Company Profiles
11.1. Abbott
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Teva Pharmaceutical Industries Ltd.
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GSK plc.
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Eli Lilly and Company
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. LTE Scientific
11.5. Cipla Inc.
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Novartis AG
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. AstraZeneca
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Alkermes
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Mallinckrodt
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
Chapter 12. Research Methodology
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
Chapter 13. Appendix
13.1. About Us
13.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers